IV Equipment Market To Progress At A Healthy CAGR In Coming Years

 Expected Revenue Growth:

The overall IV equipment market is expected to grow from USD 10.07 billion in 2017 to USD 13.64 billion by 2022, at a CAGR of 6.2% from 2017 to 2022.

What This Report Will Provide?

The global burden of chronic diseases such as heart disease, stroke, cancer, chronic respiratory diseases, and diabetes is increasing rapidly. According to the World Health Organization (WHO) 2015, chronic diseases accounted for approximately 60% of the total reported deaths in the world. The proportion of the burden of chronic diseases (chronic non-communicable diseases) is expected to increase to 57% by 2020 from 46% in 2001.

Major Growth Boosters:

Intravenous (IV) therapy devices are used to administer liquid substances directly into a vein. They can deliver nutrients or medications such as insulin or other hormones, antibiotics, chemotherapy drugs, and pain relievers. Presently, many companies are developing various infusion devices capable of being integrated with alarm devices, monitoring devices, and data exchange systems. This integration helps prevent an overdose or reduced dose of infusion solutions to patients and minimizes dosing errors.

Download PDF Brochure:  https://www.marketsandmarkets.com/requestsampleNew.asp?id=78345313 

Objectives of the Study

• To define, describe, and forecast the global IV equipment market on the basis of product, end user, and region
• To provide detailed information regarding the major factors influencing the growth of the market (drivers, restraints, opportunities, challenges, and trends)
• To strategically analyze micromarkets1 and subsegments with respect to individual growth trends, future prospects, and contributions to the overall market
• To analyze the opportunities in the market for stakeholders and provide details of a competitive landscape for market leaders
• To forecast the size of the IV equipment market, with respect to four main regions—North America, Europe, Asia-Pacific, and the Rest of the World

Major Market Developments

• In 2015, Becton, Dickinson and Company acquired CareFusion Corporation (US). The combination of these two companies’ complementary product portfolios offered integrated medication management solutions and smart devices, including infusion pumps.
• In 2017, BD launched a new IV medication safety solution at the European Association of Hospital Pharmacists (EAHP, Cannes) congress to improve patient safety. This product is designed to prevent medication administration errors.
• In October 2017, ICU Medical, Inc. acquired Pfizer's Hospira infusion systems (HIS, U.S.) business segment with a comprehensive portfolio of complete IV therapy from pumps to solutions.

Request Sample Report:  https://www.marketsandmarkets.com/requestsampleNew.asp?id=78345313 

Increasing incidence of chronic diseases and rising geriatric population, growing number of surgical procedures performed, rising demand for ambulatory infusion pumps due to the growing home care market, rising number of needlestick injuries and infections are the key factors driving the growth of this market.

Regional Growth Analysis:

The IV equipment market in APAC is expected to grow at the highest CAGR during the forecast period. The demand for IV equipment and accessories in the APAC region is majorly driven by factors such as the large population base in the region, rising geriatric population, rising incidence of chronic diseases, improving accessibility to advanced healthcare facilities, rising healthcare spending, growing penetration of health insurance, increasing demand for advanced technologies, growing investments in emerging APAC countries by key market players, and expansion of private-sector hospitals to rural areas.

Pharmacy Automation Market To Reach USD 5.38 Billion By 2022 – Increasing Investment In Retail Pharmacy

 Expected Revenue Growth:

[218 Pages Report] MarketsandMarkets forecasts the pharmacy automation market is estimated to grow from USD 3.63 billion in 2017 to USD 5.38 Billion by 2022, at a Compound Annual Growth Rate (OTC:CAGR) of 8.2% during the forecast period.

What This Report Will Provide?

The systems for managing medicines have remained largely unchanged for decades, while medications have increased in number and complexity, resulting in potentially greater risks for error. In addition, with the traditional methods of operation within pharmacies, pharmacists have witnessed various issues such as an increase in medication errors and growing patient waiting times, due to the increasing patient load.

Major Growth Boosters:

The major factors that are expected to be driving the pharmacy automation market are the growing need to minimize medication errors, rapid decentralization of pharmacies, rising geriatric population and rising labor cost. On the other hand, reluctance among the healthcare organizations to adopt pharmacy automation systems is expected to restrain the overall market growth to a certain extent during the forecast period.

The objective of the report is to define, describe, and forecast the pharmacy automation market size based on product, end user, and region.

Download PDF Brochure:  https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=71522890  

Recent Developments :

• In 2017, Omnicell launched Omnicell VBM 200F. It fills and checks SureMed multiple medication blister cards
• In 2017, Omnicell partnered with DCH Health Systems to implement a full suite of IV compounding technology across its health system
• In 2017, BD opened its new institute for medication management excellence. This institute is designed to identify and support advancements in medication management to help improve the safety and cost of healthcare
• In 2016, Omnicell acquired Ateb, Inc., which provides pharmacy-based patient care solutions and medication synchronization to independent and chain pharmacies
• In 2015, BD acquired CareFusion Corporation, a global medical technology company with a comprehensive portfolio of products in the areas of medication management, infection prevention, operating room & procedural effectiveness, and respiratory care

Critical questions the report answers:

• Where will all these developments take the industry in the long term?
• What are the upcoming trends for the pharmacy automation market?
• Which segment provides the most opportunity for growth?
• Who are the leading players operating in this market?
• What are the opportunities for new market entrants?

Request Sample Report: https://www.marketsandmarkets.com/requestsampleNew.asp?id=71522890

Growing need to minimize medication errors :

Medication errors and dispensing errors are recognized as leading causes of hospital readmissions across the globe. A medication error can occur due to a variety of factors such as poor order communication between the physician and pharmacist, dangerous storage practices in pharmacies, and confusion arising out of the use of similar labels. Automated systems are considered to be one of the most efficient solutions to minimize these errors.

Regional Growth Analysis:

North America is expected to hold the largest market size in the pharmacy automation market during the forecast period, followed by the European region. The large share of the North American pharmacy automation market can largely be attributed to the increasing number of drug prescriptions at pharmacies resulting from growth in the aging population. Furthermore, growth in insurance coverage in the U.S. has increased the burden on the country’s healthcare system, which has highlighted the need for improving efficiency and management of work in North America and also the presence of a large number of pharmacy automation companies.

Analytical Laboratory Services To Reach USD 333.8 Million By 2021 : Market Growing Expenditure On Drugs And Medical Devices

 What This Report Will Provide?

The key trends for increase in market, by public health organization are the growing expenditure on drugs and medical devices by public health organizations, steps by the government to build up strong analytical testing abilities, increasing number of drug approvals and clinical trials, and rising demand for specialized analytical testing services. However, complex and innovative pharmaceutical products requiring a distinctive analytical testing approach is the major challenge hampering the growth of government support.

Expected Revenue Growth:

[68 Pages Report] The global analytical laboratory services market, by public health organization is projected to reach USD 333.8 Million by 2021 from USD 202.8 Million in 2016, at a CAGR of around 10.5% during the forecast period.

Major Growth Boosters:

The overall market, by public health organization is positively impacted by factors such as the growing expenditure on drugs and medical devices by public health organizations, government initiatives to strengthen analytical testing capabilities, increasing number of drug approvals & clinical trials, and rising demand for specialized analytical testing services.However, complex and innovative pharmaceutical products requiring a distinctive analytical testing approach is the major challenge hampering the growth of government support on analytical laboratory services.

Download PDF Brochure:   https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=65590498 

Target Audience

• Government Agencies
• Nonprofit Organizations
• Analytical Laboratories
• Private Analytical Testing Providers

On the basis of type of service, the spend assessment is segmented into eight segments, namely, bioanalytical testing, batch release testing, stability testing, raw material testing, physical characterization, method validation, microbial testing, and environmental monitoring. In 2015, the bioanalytical testing segment accounted for the largest share of the analytical laboratory services market, by public health organization. T

Request Sample Report:   https://www.marketsandmarkets.com/requestsampleNew.asp?id=65590498 

Increasing number of CROs providing HCS services

HCS is used in several stages of the drug discovery process, including primary and secondary screening, target identification and validation and toxicity studies. As HCS instruments are expensive, they add to the overall drug development expense for pharmaceutical and biopharmaceutical companies. Moreover, budgetary restrictions among academic institutes restrict the purchase of these instruments.

Regional Growth Analysis:

Geographically, the market, by public health organization is segmented into North America, Europe, Asia-Pacific, and the Rest of the World (RoW). In 2015, North America commanded the largest share, followed by Europe, Asia-Pacific, and the RoW. The major share of this region can be attributed to the high expenditure on quality testing, strong regulatory scenario, increasing number of clinical trials, and the well-established federal testing laboratories in the region. Moreover, Asia-Pacific is expected to grow at the highest CAGR during the forecast period.

Non Invasive Prenatal Testing (NIPT) Market Worth USD 7.3 Billion : Key Industry Insights, Current And Future Perspectives

 Major Growth Boosters:

Growth in this market is driven by the high risk of chromosomal abnormalities with increasing maternal age, growing preference for non-invasive techniques over invasive methods, improving reimbursement scenario for NIPT, and increasing awareness of NIPT. However, a dearth of skilled professionals is restraining the growth of this market.

Expected Revenue Growth:

[144 Pages Report] The global non-invasive prenatal testing (NIPT) market is estimated to reach USD 7.3 billion by 2024 from USD 3.9 billion in 2019, at a CAGR of 13.5% during the forecast period.

What This Report Will Provide?

The study involved four major activities in estimating the current size of the global non-invasive prenatal testing market. Exhaustive secondary research was done to collect information on the market, its peer markets, and its parent market. The next step was to validate these findings, assumptions, and sizing values with industry experts across the value chain through primary research.

Download PDF Brochure:   https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=145607690  

Recent Developments :

• In June 2019, BGI and Eluthia (Germany) launched the NIFTY test (non-invasive prenatal test), under the brand name PreviaTest in Germany.
• In January 2019, Illumina expanded its NIPT platform with the launch of VeriSeq NIPT Solution v2.
• In November 2018, Illumina and Pacific Biosciences signed an agreement for Illumina to acquire Pacific Biosciences. This acquisition will allow Illumina to strengthen its sequencing solutions platform with accurate long-read sequencing capabilities.
• In January 2017, Agilent Technology acquired Multiplicom N.V. (Belgium) in order to create comprehensive offerings for next-generation sequencing solutions. Multiplicom develops and commercializes molecular diagnostic solutions which are useful in the identification of congenital defects early in pregnancy and other genetic diseases

Key Questions Addressed by the Report :

• Where will all these developments take the industry in the mid to long-term?
• What types of annual and multi-year partnerships are NIPT product and service companies exploring?
• Which are the key players in the market and how intense is the competition?
• Which are the recent contracts and agreements key players have signed?
• What are the recent trends affecting NIPT product and service providers?

Request Sample Report:  https://www.marketsandmarkets.com/requestsampleNew.asp?id=145607690  

The cfDNA in maternal plasma tests segment is expected to grow at the highest CAGR during the forecast period

By method, the NIPT products market is segmented into ultrasound detection, biochemical screening tests, and cell-free DNA in maternal plasma tests. The cfDNA in maternal plasma tests segment is expected to grow at the highest CAGR during the forecast period. The high growth of this segment is attributed to technological advancements and increasing company initiatives to develop new products.

Regional Growth Analysis:

Geographically, the non-invasive prenatal testing market is segmented into North America, Europe, Asia, and the Rest of the World (RoW). In 2019, North America accounted for the largest market share, followed by Europe. On the other hand, Asia is expected to grow at the highest CAGR during the forecast period. The developing healthcare infrastructure, rising awareness programs & conferences, and rising focus of prominent players on expanding their presence in Asia are driving market growth in this region

Glycomics Market Worth USD 2.0 Billion : Key Industry Insights, Current And Future Perspectives

 Major Growth Boosters:

The growth of this market is majorly driven by the increasing research activities on glycomics, rising R&D investments in pharmaceutical and biotechnology companies, growth in the proteomics market. On the other hand, emerging countries such as India and China providing lucrative opportunities for players operating in this segment.

Expected Revenue Growth:

[173 Pages Report] The global glycomics market is estimated to grow from USD 1.0 billion in 2020 to USD 2.0 billion by 2025, at a CAGR of 13.8%.

What This Report Will Provide?

This study involved four major activities in estimating the current size of the glycomics market. Exhaustive secondary research was carried out to collect information on the market, its peer markets, and its parent market. The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain through primary research.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=132685525

The demand for glycomics products for drug discovery & development is estimated to grow at a high rate during the forecast period

Based on application, the glycomics market is segmented into drug discovery & development, disease diagnostics, and other applications. Drug discovery & development is the largest and the fastest-growing application segment in the market, majorly due to the increasing R&D investments in pharmaceutical and biotechnology companies and the growing number of drug discovery research activities in academic research institutes.

Developments:

• In June 2019, Agilent Technologies (US) has launched InfinityLab LC/MSD iQ System
• In June 2018, Thermo Fisher Scientific (US) had launched UHMR Hybrid Quadrupole-Orbitrap Mass Spectrometer.

Key Questions Addressed in The Report:

• Where will all these developments take the industry in the mid-to-long term?
• What are the recent trends affecting the glycomics market?
• Who are the key players in the market, and how intense is the competition?
• What are the key applications of glycomics?
• Which region is lucrative for the market?

Request Sample Report: https://www.marketsandmarkets.com/requestsampleNew.asp?id=132685525

Regional Growth Analysis:

The global glycomics market is segmented into North America (US and Canada), Europe (Germany, the UK, France, Italy, Spain, and the Rest of Europe), Asia Pacific (Japan, China, India, Australia, and the Rest of Asia Pacific), and the Rest of the World (Latin America and the Middle East and Africa). In 2020, North America is expected to dominate the global market, followed by Europe. The largest share of North America is mainly attributed to increasing investments in glycomics research, rising R&D investments in pharmaceutical companies for drug discovery and the presence of all key players.

Women’s Health Diagnostics Market : Key Industry Insights, Current And Future Perspectives

 COVID-19 Impact on Global Women’s Health Diagnostics Market :

Since the beginning of 2020, more and more countries across the globe shut down their borders and limited transportation and travel to contain the coronavirus (COVID-19) outbreak, thus, creating impediments for international trade and transportation. This had disrupted the supply chains for the women’s health diagnostics market, temporarily leading to fall in demand due to uncertainty in the global economy and capital markets.

Expected Revenue Growth:

The women’s health diagnostics market is projected to reach USD 36.6 billion by 2025 from USD 25.0 billion in 2020, at a CAGR of 7.9% during the forecast period.

What This Report Will Provide?

This study involved the extensive use of both primary and secondary sources. The research process involved the study of various factors affecting the industry to identify the segmentation types, industry trends, key players, competitive landscape, key market dynamics, and key player strategies.

Diagnostic tests such as POC tests are commonly used to detect HIV among patients. A rapid POC HIV test enables physicians to provide results and the HIV status of patients during the same visit. It does not require pre-test and post-test counseling of patients, as is common during traditional laboratory analysis.

Download PDF Brochure:  https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=128928901 

Recent Developments

• In 2021, F. Hoffmann-La Roche Ltd. Launched the uPath HER2 (4B5) Image Analysis and uPath Dual ISH Image Analysis.
• In 2021, Hologic, Inc. acquired Biotheranostics, a privately held, commercial-stage company that provides molecular diagnostic tests for breast and metastatic cancers, to strengthen its presence in the women’s health diagnostics market.
• In 2020, Hologic, Inc. launched the 3DQuorum Imaging Technology in Europe.
• In 2019, Carestream Health, Inc. opened a new global business operations center in Mumbai, India, expanding its market presence.

Frequently Asked Questions (FAQs) :

• Which are the top industry players in the global women’s health diagnostics market?
• Which global women’s health diagnostics appications have been included in this report?
• Which geographical region is dominating in the global women’s health diagnostics market?
• Which is the leading global women’s health diagnostics end user segment?

Request Sample Report:   https://www.marketsandmarkets.com/requestsampleNew.asp?id=128928901 

Major Growth Boosters:

The market is mainly driven by growing awareness about various health-related disorders, rising incidence of chronic and lifestyle disorders, and the high prevalence of infectious diseases such as HIV and hepatitis in women across the globe.

The increasing adoption of POC diagnostic testing and the growth in the number of diagnostic and imaging centers are also expected to support the growth of this market during the forecast period.

Regional Growth Analysis:

In 2019, North America accounted for the largest share of the women’s health diagnostics market, followed by Europe, the Asia Pacific, Latin America, and the Middle East & Africa. The large share of this market segment can be attributed to the increasing prevalence of cancer among women, the growing focus of manufacturers of women’s health diagnostic products on expanding their presence in this region, and the increasing demand for fertility testing monitors.

Women’s Health Diagnostics Market : Key Industry Insights, Current And Future Perspectives

 COVID-19 Impact on Global Women’s Health Diagnostics Market :

Since the beginning of 2020, more and more countries across the globe shut down their borders and limited transportation and travel to contain the coronavirus (COVID-19) outbreak, thus, creating impediments for international trade and transportation. This had disrupted the supply chains for the women’s health diagnostics market, temporarily leading to fall in demand due to uncertainty in the global economy and capital markets.

Expected Revenue Growth:

The women’s health diagnostics market is projected to reach USD 36.6 billion by 2025 from USD 25.0 billion in 2020, at a CAGR of 7.9% during the forecast period.

What This Report Will Provide?

This study involved the extensive use of both primary and secondary sources. The research process involved the study of various factors affecting the industry to identify the segmentation types, industry trends, key players, competitive landscape, key market dynamics, and key player strategies.

Diagnostic tests such as POC tests are commonly used to detect HIV among patients. A rapid POC HIV test enables physicians to provide results and the HIV status of patients during the same visit. It does not require pre-test and post-test counseling of patients, as is common during traditional laboratory analysis.

Download PDF Brochure:  https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=128928901 

Recent Developments

• In 2021, F. Hoffmann-La Roche Ltd. Launched the uPath HER2 (4B5) Image Analysis and uPath Dual ISH Image Analysis.
• In 2021, Hologic, Inc. acquired Biotheranostics, a privately held, commercial-stage company that provides molecular diagnostic tests for breast and metastatic cancers, to strengthen its presence in the women’s health diagnostics market.
• In 2020, Hologic, Inc. launched the 3DQuorum Imaging Technology in Europe.
• In 2019, Carestream Health, Inc. opened a new global business operations center in Mumbai, India, expanding its market presence.

Frequently Asked Questions (FAQs) :

• Which are the top industry players in the global women’s health diagnostics market?
• Which global women’s health diagnostics appications have been included in this report?
• Which geographical region is dominating in the global women’s health diagnostics market?
• Which is the leading global women’s health diagnostics end user segment?

Request Sample Report:   https://www.marketsandmarkets.com/requestsampleNew.asp?id=128928901 

Major Growth Boosters:

The market is mainly driven by growing awareness about various health-related disorders, rising incidence of chronic and lifestyle disorders, and the high prevalence of infectious diseases such as HIV and hepatitis in women across the globe.

The increasing adoption of POC diagnostic testing and the growth in the number of diagnostic and imaging centers are also expected to support the growth of this market during the forecast period.

Regional Growth Analysis:

In 2019, North America accounted for the largest share of the women’s health diagnostics market, followed by Europe, the Asia Pacific, Latin America, and the Middle East & Africa. The large share of this market segment can be attributed to the increasing prevalence of cancer among women, the growing focus of manufacturers of women’s health diagnostic products on expanding their presence in this region, and the increasing demand for fertility testing monitors.